Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon

What this Trial Is About

Researchers are evaluating whether a suprachoroidal injection of triamcinolone can treat vision-threatening swelling in the center of the retina, called macular edema, caused by non-infectious uveitis. This study focuses especially on patients who did not improve after receiving a standard steroid injection around the eye (sub-Tenon injection). The main questions include whether vision improves on the eye chart and if retinal swelling decreases within three months after the injection. Participants will receive one suprachoroidal triamcinolone injection delivered using a custom-made device with controlled needle depth under anesthetic eye drops in a sterile setting. The study includes a pretreatment check with vision tests, slit-lamp examination, and an OCT retinal scan. Follow-up visits will occur about one month and three months after treatment to repeat vision tests and OCT scans. During the study, participants will be monitored for vision improvement and reduction in retinal thickness. They are asked to contact the clinic if they experience pain, redness, new floaters, or worsening vision. The primary outcome measure is visual acuity improvement at three months, with central macular thickness as a secondary outcome. The total participation duration includes screening, treatment, and follow-up over three months.

Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon